Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.

Saved in:
Bibliographic Details
Title: Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.
Authors: Shapiro DD; University of Wisconsin School of Medicine and Public Health, Madison, WI; William S. Middleton Memorial Veterans Hospital, Madison, WI. Electronic address: ddshapiro@wisc.edu., Abel EJ; University of Wisconsin School of Medicine and Public Health, Madison, WI., Albiges L; Institut Gustave Roussy, Paris, France., Battle D; Kidney Cancer Research Alliance, Alexandria, VA., Berg SA; Dana-Farber Cancer Institute, Boston, MA., Campbell MT; The University of Texas MD Anderson Cancer Center, Houston, TX., Cella D; Northwestern University Feinberg School of Medicine, Chicago, IL., Coleman K; Chromophobe and Oncocytic Tumor Alliance, Austin, TX., Garmezy B; Sarah Cannon Research Institute, Nashville, TN., Geynisman DM; Fox Chase Cancer Center, Philadelphia, PA., Hall T; Exelixis, Alameda, CA., Henske EP; Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Jonasch E; The University of Texas MD Anderson Cancer Center, Houston, TX., Karam JA; The University of Texas MD Anderson Cancer Center, Houston, TX., La Rosa S; Kidney Cancer Association, Houston, TX., Leibovich BC; Mayo Clinic, Rochester, MN., Maranchie JK; University of Pittsburgh, Pittsburgh, PA., Master VA; Emory University, Winship Cancer Center, Atlanta, GA., Maughan BL; University of Utah, Salt Lake City, UT., McGregor BA; Dana-Farber Cancer Institute, Boston, MA., Msaouel P; The University of Texas MD Anderson Cancer Center, Houston, TX., Pal SK; City of Hope Comprehensive Cancer Center, Duarte, CA., Perez J; Exelixis, Alameda, CA., Plimack ER; Fox Chase Cancer Center, Philadelphia, PA., Psutka SP; University of Washington School of Medicine, Seattle, WA., Riaz IB; Mayo Clinic College of Medicine and Sciences, Phoenix, AZ., Rini BI; Vanderbilt University, Nashville, TN., Shuch B; David Geffen School of Medicine, UCLA, Los Angeles, CA., Simon MC; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Singer EA; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Smith A; St Jude Children's Research Hospital, Memphis, TN., Staehler M; Ludwig-Maximilians University of Munich, Munich, Germany., Tang C; The University of Texas MD Anderson Cancer Center, Houston, TX., Tannir NM; The University of Texas MD Anderson Cancer Center, Houston, TX., Vaishampayan U; University of Michigan School of Medicine, Ann Arbor, MI., Voss MH; Memorial Sloan Kettering Cancer Center, New York, NY., Zakharia Y; Mayo Clinic College of Medicine and Sciences, Phoenix, AZ., Zhang Q; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX., Zhang T; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX., Carlo MI; Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: carlom@msckcc.org.
Source: Urologic oncology [Urol Oncol] 2025 Nov; Vol. 43 (11), pp. 639-653. Date of Electronic Publication: 2025 Aug 16.
Publication Type: Journal Article; Consensus Statement; Review
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 9805460 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2496 (Electronic) Linking ISSN: 10781439 NLM ISO Abbreviation: Urol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2496
DOI:10.1016/j.urolonc.2025.07.020